HealthEquity (NASDAQ:HQY – Get Free Report) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.880-2.950 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of -.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on HQY shares. Royal Bank Of Canada dropped their target price on HealthEquity from $110.00 to $100.00 and set an “outperform” rating for the company in a research report on Wednesday, March 18th. BMO Capital Markets upgraded HealthEquity from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $85.00 to $105.00 in a report on Thursday, April 9th. Barclays reduced their price target on HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, February 18th. KeyCorp reiterated an “overweight” rating on shares of HealthEquity in a report on Tuesday. Finally, Raymond James Financial set a $100.00 price target on HealthEquity in a report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.79.
HealthEquity Stock Performance
HealthEquity (NASDAQ:HQY – Get Free Report) last posted its quarterly earnings data on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.11 by $0.13. HealthEquity had a net margin of 16.39% and a return on equity of 13.86%. The business had revenue of $354.64 million during the quarter, compared to the consensus estimate of $352.02 million. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts predict that HealthEquity will post 3.84 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Sivia Capital Partners LLC purchased a new position in shares of HealthEquity in the 2nd quarter valued at $306,000. Kemnay Advisory Services Inc. purchased a new position in shares of HealthEquity in the 4th quarter valued at $94,000. Johnson Investment Counsel Inc. purchased a new position in shares of HealthEquity in the 4th quarter valued at $212,000. Smartleaf Asset Management LLC grew its position in shares of HealthEquity by 51.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 793 shares of the company’s stock valued at $73,000 after buying an additional 271 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in shares of HealthEquity by 14.3% in the 4th quarter. Parallel Advisors LLC now owns 1,387 shares of the company’s stock valued at $127,000 after buying an additional 173 shares during the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.
About HealthEquity
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Read More
- Five stocks we like better than HealthEquity
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
